Yu Erica Lee

Yu Erica Lee

Auto-generated profile, based on publicly available information

Yu Erica Lee

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Science
Verified
Journal Article
Open access
PDF file
ACAlexander A. Cohen
Alexander A. Cohen
PGPriyanthi N. P. Gnanapragasam
Priyanthi N. P. Gnanapragasam
YLYu E. Lee
Yu E. Lee
PHPauline R. Hoffman
Pauline R. Hoffman
SOSusan Ou
Susan Ou
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
Fighting zoonotic coronaviruses: In the past 20 years, three betacoronaviruses thought to have originated in bats have caused devastating disease in humans. The global pandemic caused by the latest such virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlights the need to protect against other strains that could present a threat to humans. Cohen et al. constructed nanoparticles displaying the protein domain that binds the host cell receptor (receptor-binding domain or RBD), either a homotypic SARS-CoV-2 particle or mosaic particles displaying RBDs from four or eight different betacoronaviruses. In mice, antibodies to the SARS-CoV-2 RBD were elicited just as well by mosaic particles as by homotypic nanoparticles. The mosaic nanoparticles elicited antibodies that, beyond recognizing the strains displayed, also recognized mismatched strains. Science , this issue p. 735

5 August 2022 in Science
Verified
Journal Article
Open access
ACAlexander A. Cohen
Alexander A. Cohen
NDNeeltje van Doremalen
Neeltje van Doremalen
AGAllison J. Greaney
Allison J. Greaney
HEHanne Andersen Andersen Elyard
Hanne Andersen Andersen Elyard
ASAnkur Sharma
Ankur Sharma
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, we designed mosaic nanoparticles that present randomly arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against epitopes that are conserved and relatively occluded rather than variable, immunodominant, and exposed. We compared immune responses elicited by mosaic-8 (SARS-CoV-2 and seven animal sarbecoviruses) and homotypic (only SARS-CoV-2) RBD nanoparticles in mice and macaques and observed stronger responses elicited by mosaic-8 to mismatched (not on nanoparticles) strains, including SARS-CoV and animal sarbecoviruses. Mosaic-8 immunization showed equivalent neutralization of SARS-CoV-2 variants, including Omicrons, and protected from SARS-CoV-2 and SARS-CoV challenges, whereas homotypic SARS-CoV-2 immunization protected only from SARS-CoV-2 challenge. Epitope mapping demonstrated increased targeting of conserved epitopes after mosaic-8 immunization. Together, these results suggest that mosaic-8 RBD nanoparticles could protect against SARS-CoV-2 variants and future sarbecovirus spillovers.

1 September 2021 in Cell Reports
Verified
Journal Article
Open access
CJClaudia A. Jette
Claudia A. Jette
ACAlexander A. Cohen
Alexander A. Cohen
PGPriyanthi N.P. Gnanapragasam
Priyanthi N.P. Gnanapragasam
FMFrauke Mücksch
Frauke Mücksch
YLYu E. Lee
Yu E. Lee
CBChristopher O. Barnes
Christopher O. Barnes
Many anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) neutralizing antibodies target the angiotensin-converting enzyme 2 (ACE2) binding site on viral spike receptor-binding domains (RBDs). Potent antibodies recognize exposed variable epitopes, often rendering them ineffective against other sarbecoviruses and SARS-CoV-2 variants. Class 4 anti-RBD antibodies against a less-exposed, but more-conserved, cryptic epitope could recognize newly emergent zoonotic sarbecoviruses and variants, but they usually show only weak neutralization potencies. Here, we characterize two class 4 anti-RBD antibodies derived from coronavirus disease 2019 (COVID-19) donors that exhibit breadth and potent neutralization of zoonotic coronaviruses and SARS-CoV-2 variants. C118-RBD and C022-RBD structures reveal orientations that extend from the cryptic epitope to occlude ACE2 binding and CDRH3-RBD main-chain H-bond interactions that extend an RBD β sheet, thus reducing sensitivity to RBD side-chain changes. A C118-spike trimer structure reveals rotated RBDs that allow access to the cryptic epitope and the potential for intra-spike crosslinking to increase avidity. These studies facilitate vaccine design and illustrate potential advantages of class 4 RBD-binding antibody therapeutics.

8 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MAMarianna Agudelo
Marianna Agudelo
Martin PalusMartin Palus
Martin Palus
JKJennifer R. Keeffe
Jennifer R. Keeffe
FBFilippo Bianchini
Filippo Bianchini
Pavel SvobodaPavel Svoboda
Pavel Svoboda
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Tick-borne encephalitis virus (TBEV) is an emerging human pathogen that causes potentially fatal disease with no specific treatment. Mouse monoclonal antibodies are protective against TBEV, but little is known about the human antibody response to infection. Here, we report on the human neutralizing antibody response to TBEV in a cohort of infected and vaccinated individuals. Expanded clones of memory B cells expressed closely related anti-envelope domain III (EDIII) antibodies in both groups of volunteers. However, the most potent neutralizing antibodies, with IC50s below 1 ng/ml, were found only in individuals who recovered from natural infection. These antibodies also neutralized other tick-borne flaviviruses, including Langat, louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and Powassan viruses. Structural analysis revealed a conserved epitope near the lateral ridge of EDIII adjoining the EDI–EDIII hinge region. Prophylactic or early therapeutic antibody administration was effective at low doses in mice that were lethally infected with TBEV.

12 August 2022 in Science Advances
Verified
Journal Article
Open access
CBChristopher O. Barnes
Christopher O. Barnes
TSTill Schoofs
Till Schoofs
PGPriyanthi N.P. Gnanapragasam
Priyanthi N.P. Gnanapragasam
JGJovana Golijanin
Jovana Golijanin
KHKathryn E. Huey-Tubman
Kathryn E. Huey-Tubman
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine against HIV-1. However, most bNAbs exhibit features such as unusually high somatic hypermutation, including insertions and deletions, which make their induction challenging. VRC01-class bNAbs not only exhibit extraordinary breadth and potency but also rank among the most highly somatically mutated bNAbs. Here, we describe a VRC01-class antibody isolated from a viremic controller, BG24, that is much less mutated than most relatives of its class while achieving comparable breadth and potency. A 3.8-Å x-ray crystal structure of a BG24-BG505 Env trimer complex revealed conserved contacts at the gp120 interface characteristic of the VRC01-class Abs, despite lacking common CDR3 sequence motifs. The existence of moderately mutated CD4-binding site (CD4bs) bNAbs such as BG24 provides a simpler blueprint for CD4bs antibody induction by a vaccine, raising the prospect that such an induction might be feasible with a germline-targeting approach.

5 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
ARAdonis A. Rubio
Adonis A. Rubio
VBViren A. Baharani
Viren A. Baharani
BDBernadeta Dadonaite
Bernadeta Dadonaite
MPMegan Parada
Megan Parada
MAMorgan Elizabeth Abernathy
Morgan Elizabeth Abernathy
CBChristopher O. Barnes
Christopher O. Barnes
The ongoing emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation antibody modalities that are resilient to viral evolution. Here, we characterized amino-terminal domain (NTD)– and receptor binding domain (RBD)–specific monoclonal antibodies previously isolated from coronavirus disease 2019 (COVID-19) convalescent donors for their activity against emergent SARS-CoV-2 VOCs. Among these, the NTD-specific antibody C1596 displayed the greatest breadth of binding to VOCs, with cryo–electron microscopy structural analysis revealing recognition of a distinct NTD epitope outside of the site i antigenic supersite. Given C1596’s favorable binding profile, we designed a series of bispecific antibodies (bsAbs), termed CoV2-biRNs, that featured both NTD and RBD specificities. Two of the C1596-inclusive bsAbs, CoV2-biRN5 and CoV2-biRN7, retained potent in vitro neutralization activity against all Omicron variants tested, including XBB.1.5, BA.2.86, and JN.1, contrasting the diminished potency of parental antibodies delivered as monotherapies or as a cocktail. Furthermore, prophylactic delivery of CoV2-biRN5 reduced the viral load within the lungs of K18-hACE2 mice after challenge with SARS-CoV-2 XBB.1.5. In conclusion, NTD-RBD bsAbs offer promising potential for the design of resilient, next-generation antibody therapeutics against SARS-CoV-2 VOCs.